73 completed, 28 unknown, 15 active not recruiting, 10 recruiting. 139 Phase 3, 6 Phase 2.
Follow Tamoxifen: new trials by email Literature Review of Tamoxifen trials Research Report on Tamoxifen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery Adjuvant Radiotherapy, tamoxifen - Ductal Carcinoma In Situ, DCIS | Phase 3 | Recruiting | Fudan University | 636 | 2026-07-01 | 2026-08-13 |
| A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets - Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 5500 | 2026-03-04 | 2026-05-22 |
| CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibitor - Breast Cancer, Adjuvant Therapy | Phase 3 | Recruiting | Fudan University | 1903 | 2025-06-15 | 2026-01-21 |
| Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer Letrozole, Anastrozole, Exemestane - Breast Cancer | Phase 3 | Not yet recruiting | Region Örebro County | 3832 | 2025-05-02 | 2025-04-20 |
| Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial Anastrozole, Letrozole, Exemestane - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8 | Phase 3 | Suspended | Alliance for Clinical Trials in Oncology | 1556 | 2025-02-19 | 2026-09-02 |
| Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) Endocrine therapy + Abemaciclib, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen - Breast Cancer, Locoregional Recurrence | Phase 3 | Recruiting | Japanese Foundation for Cancer Research | 290 | 2025-02-07 | 2025-09-29 |
| External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women with Severe Mastalgia mastalgia-oil, tamoxifen placebo, mastalgia-oil placebo, tamoxifen - Mastalgia | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 456 | 2025-01-16 | 2024-11-29 |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence Elacestrant, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Active not recruiting | Stemline Therapeutics, Inc. | 4556 | 2024-09-27 | 2026-11-04 |
| Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. T Leuprolide Injectable Emulsion, Leuprorelin Acetate Microspheres for Injection - Breast Cancer Subjects | Phase 3 | Active not recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 211 | 2024-08-21 | 2025-10-01 |
| A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy Fezolinetant, Placebo, Tamoxifen - Hot Flashes | Phase 3 | Active not recruiting | Astellas Pharma Global Development, Inc. | 982 | 2024-07-31 | 2026-10-27 |
| Pre-Operative Window of ET to Inform RT Decisions (POWER II) Tamoxifen, Letrozole, Anastrozole, or Exemestane - Breast Cancer Female | Phase 3 | Recruiting | University of Virginia | 354 | 2024-07-19 | 2026-06-30 |
| Maintenance Hormonal Therapy and DLBCL Tamoxifen 20mg - Diffuse Large B Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Sohag University | 100 | 2024-04-01 | 2024-04-09 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Camizestrant, Tamoxifen, Anastrozole - Breast Cancer, Early Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 5511 | 2023-10-05 | 2026-08-10 |
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) Fluzoparib, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Recruiting | Fudan University | 766 | 2023-06-01 | 2024-02-08 |
| Letrozole vs. Clomiphene Citrate Plus Tamoxifen for Ovulation Induction and Pregnancy Outcomes. Letrozole, Clomiphene Citrate + Tamoxifen - Infertility Drugs, Infertility Involuntary | Phase 3 | Active not recruiting | Sana'a University | 240 | 2023-05-01 | 2026-06-01 |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Camizestrant, Tamoxifen, Anastrozole - Breast Cancer, Early Breast Cancer | Phase 3 | Recruiting | AstraZeneca | 4300 | 2023-03-31 | 2026-10-13 |
| Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole, Anastrozole, Tamoxifen - Breast Cancer | Phase 3 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1946 | 2023-03-30 | 2026-04-17 |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study TOL2506, Tamoxifen, Letrozole tablets - Breast Cancer | Phase 3 | Enrolling by invitation | Tolmar Inc. | 250 | 2022-12-28 | 2026-10-23 |
| A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Imlunestrant, Tamoxifen, Anastrozole - Breast Neoplasms | Phase 3 | Active not recruiting | Eli Lilly and Company | 8000 | 2022-10-04 | 2026-04-02 |
Showing 20 of 139. Sign in to see all of them.
Breast Neoplasms (112) · Carcinoma, Intraductal, Noninfiltrating (9) · Breast Carcinoma In Situ (6) · Neoplasm Metastasis (4) · Neoplasms (4) · Breast Neoplasms, Male (3) · Carcinoma, Ductal, Breast (3) · Inflammatory Breast Neoplasms (3) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Infertility (2) · Anovulation (1) · Bipolar Disorder (1) · Breast Diseases (1) · Carcinoma, Hepatocellular (1)
AstraZeneca (13) · ETOP IBCSG Partners Foundation (8) · National Cancer Institute (NCI) (8) · Scottish Cancer Therapy Network (6) · NSABP Foundation Inc (5) · SWOG Cancer Research Network (4) · Austrian Breast & Colorectal Cancer Study Group (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Fudan University (3) · NCIC Clinical Trials Group (3) · Pfizer (3) · Alliance for Clinical Trials in Oncology (2) · Eastern Cooperative Oncology Group (2) · Eli Lilly and Company (2) · European Institute of Oncology (2)
United States (43) · United Kingdom (31) · Canada (26) · Italy (26) · France (20) · China (19) · Germany (18) · Switzerland (15) · Australia (14) · Belgium (14) · Hungary (14) · Spain (13) · Netherlands (12) · Argentina (11) · Brazil (11)
Raimund Jakesz, MD (4) · W.D. George, MD, MS, FRCS (3) · Barbara L. Smith, MD, PhD (2) · Clifford A. Hudis, MD (2) · Daniel Rea, MD (2) · Edith A. Perez, MD (2) · Jack Cuzick, PhD (2) · James N. Ingle, MD (2) · Norman Wolmark, MD (2) · R. Charles Coombes, MD, MRCP, FRCP, PhD, FMedSci (2) · Robert Paridaens, MD, PhD (2)
PMID 21247627, PMID 24091623, PMID 24881463, PMID 29885375, PMID 35100692, PMID 41642493, PMID 25495490, PMID 26092816, PMID 26276354, PMID 27044936, PMID 27557300, PMID 28732650, PMID 28911092, PMID 29863451, PMID 31618131, PMID 36521078, PMID 36791166, PMID 38979716, PMID 39621968, PMID 40017004, PMID 40633461, PMID 40986647, PMID 41637791, PMID 41980703, PMID 10076721, PMID 10076722, PMID 10458221, PMID 10663329, PMID 11972444, PMID 12243915, PMID 12490681, PMID 12804433, PMID 14559892, PMID 14659350, PMID 14760111, PMID 15014181, PMID 15100340, PMID 15632378, PMID 15837982, PMID 15837984, PMID 15894097, PMID 16236738, PMID 16344321, PMID 16361630, PMID 16382061, PMID 16421418, PMID 16598749, PMID 16606972, PMID 16730270, PMID 16754727
U10CA032102 (5), 2005 (3), 2004 (2), 2023 (2), U10CA031946 (2), U10CA180821 (2), U10CA180868 (2), 2008 (1), 2009 (1), 2014 (1), P50CA083639 (1), R13AG020218 (1), U10CA021115 (1), U10CA025224 (1), U10CA027469 (1)